E-cadherin immunoexpression in complete and partial hydatidiform mole
Abstract
ABSTRACT
Aim: The aim of the study was to estimate the correlation between E-cadherin immunoexpression and patohistological features of hydatidiform moles (HM) evacuated during the first trimester of pregnancy.
Material and methods: Research was performed on 100 samples of paraffin embedded with both 50 complete and 50 partial HM, with a confirmed diagnosis following a second pathologist review. Semi-quantitative analysis of the patohistological features of the mole (hydrops of villi, trophoblast proliferation, trophoblast pseudoinclusions, trophoblast nuclear atypia) was performed as well as E-cadherin immunostaining of representative slides. The pattern of E-cadherin immunoexpression was scored semi-quantitatively for intensity of staining and percentage of positive cells among villous cytotrophoblasts.
Results: Trophoblast pseudoinclusions, a common feature in partial but not complete moles, showed a strong positive correlation with E-cadherin expression intensity but not with the percentage of positive cells. Hydrops, trophoblast proliferation, and trophoblast nuclear atypia showed a strong negative correlation with E-cadherin expression, both in intensity of expression and percentage of positive cells.
Conclusion: Trophoblast pseudoinclusions in first trimester molar specimen, are a strong indicator of the benign potential of partial moles.
Keywords
References
REFERENCES
Van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65(23):3756–88.
Bi Y, Huang W, Yuan L, Chen S, Liao S, Fu X, et al. HOXA10 improves endometrial receptivity by upregulating E-cadherin. Biol Reprod. 2022;106(5):992–9.
Niessen CM, Leckband D, Yap AS. Tissue organization by cadherin adhesion molecules: Dynamic Molecular and Cellular Mechanisms of Morphogenetic Regulation. Physiol Rev. 2011;91(2):691–731.
Lan X, Fu LJ, Hu ZY, Feng Q, Liu XQ, Zhang X, et al. Methylated oligonucleotide (MON)-induced promoter hypermethylation is associated with repression of CDH1 expression and contributes to the migration and invasion of human trophoblast cell lines. Reprod Fertil Dev. 2017;29(8):1509–20.
Szabolcsi Z, Demeter A, Kiraly P, Balogh A, Wilson ML, King JR, et al. Epigenetic dysregulation of trophoblastic gene expression in gestational trophoblastic disease. Biomedicines. 2021;9(12):1935.
Liang L, Chen Y, Wu C, Cao Z, Xia L, Meng J, et al. MicroRNAs: key regulators of the trophoblast function in pregnancy disorders. J Assist Reprod Genet. 2023;40(1):3–17.
Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C. Gestational trophoblastic disease: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):39–50.
Hafezi M, Chekini Z, Ghaffari F, Mashayekhi M, Zameni N. How Could One Sperm and One Oocyte Proceed To Molar Pregnancy? Prevalence of Molar Pregnancy during ICSI Procedure in Over 25,000 Fresh Embryo Transfers: A Retrospective Cross-Sectional Study. Int J Fertil Steril. 2023;17(1):47–51.
Petts G, Fisher RA, Short D, Lindsay I, Seckl MJ, Sebire NJ. Histopathological and immunohistochemical features of early hydatidiform mole in relation to subsequent development of persistent gestational trophoblastic disease. J Reprod Med. 2014;59(3):213–20.
Balaram P, Alex S, Panikkar B, Rajalekshmi TN. Adhesion-related proteins E-cadherin, P-cadherin, CD44, and CD44v6, and antimetastatic protein nm23H1 in complete hydatidiform moles in relation to invasion potential. Int J Gynecol Cancer. 2004;14(3):532–9.
Wang J, Zhao M, Xiao J, Wu M, Song Y, Yin Y. E-Cadherin, CD44v6, and Insulin-Like Growth Factor-II mRNA-Binding Protein 3 Expressions in Different Stages of Hydatidiform Moles. J Biochem Mol Toxicol. 2016;30(9):455–61.
Chawla T, Bouchard-Fortier G, Turashvili G, Osborne R, Hack K, Glanc P. Gestational trophoblastic disease: an update. Abdom Radiol. 2023;48(5):1793–815.
Kobayashi EH, Shibata S, Oike A, Kobayashi N, Hamada H, Okae H, et al. Genomic imprinting in human placentation. Reprod Med Biol. 2022;21(1):e12490.
Candelier JJ. The hydatidiform mole. Cell Adh Migr. 2016;10(1–2):226–35.
Novais Nogueira Cardoso RMA, Nogueira Cardoso PLN, Azevedo AP, Cadillá JS, Oliveira Rodrigues Amorim MGR, Rocha Gomes ME, et al. First-trimester miscarriage: A histopathological classification proposal. Heliyon. 2021;7(3):e06359.
Wyatt TPJ, Fouchard J, Lisica A, Khalilgharibi N, Baum B, Recho P, et al. Actomyosin controls planarity and folding of epithelia in response to compression. Nat Mater. 2020;19(1):109–17.
Kubelka-Sabit K, Prodanova I, Jasar D, Bozinovski G, Filipovski V, Drakulevski S, et al. Molecular and immunohistochemical characteristics of complete hydatidiform moles. Balk J Med Genet. 2017;20(1):27–34.
Tabacu MC, Istrate-Ofi?eru AM, Manolea MM, Dijm?rescu AL, Rotaru LT, Boldeanu MV, et al. Maternal obesity and placental pathology in correlation with adverse pregnancy outcome. Rom J Morphol Embryol. 2022;63(1):99–104.
Golfier F, Clerc J, Hajri T, Massardier J, Frappart L, Duvillard P, et al. Contribution of referent pathologists to the quality of trophoblastic diseases diagnosis. Hum Reprod. 2011;26(10):2651–7.
Sarmadi S, Izadi-Mood N, Sanii S, Motevalli D. Inter-observer variability in the histologic criteria of diagnosis of hydatidiform moles. Malays J Pathol. 2019;41(1):15–24.
Ronnett BM. Hydatidiform Moles: Ancillary Techniques to Refine Diagnosis. Arch Pathol Lab Med. 2018;142(12):1485–502.
Giacometti C, Bellan E, Ambrosi A, Dei Tos AP, Cassaro M, Ludwig K. “While there is p57, there is hope.” The past and the present of diagnosis in first trimester abortions: Diagnostic dilemmas and algorithmic approaches. A review. Placenta. 2021;116:31–7.
Joyce CM, Fitzgerald B, McCarthy T V, Coulter J, O’Donoghue K. Advances in the diagnosis and early management of gestational trophoblastic disease. BMJ Med. 2022;1(1):e000321.
Madi JM, Braga AR, Paganella MP, Litvin IE, Da Ros Wendland EM. Accuracy of p57KIP2 compared with genotyping for the diagnosis of complete hydatidiform mole: Protocol for a systematic review and meta-analysis. Syst Rev. 2016;5(1):1–6.
Lewis GH, Descipio C, Murphy KM, Haley L, Beierl K, Mosier S, et al. Characterization of androgenetic/biparental mosaic/chimeric conceptions, including those with a molar component: morphology, p57 immnohistochemistry, molecular genotyping, and risk of persistent gestational trophoblastic disease. Int J Gynecol Pathol. 2013;32(2):199–214.
Chen Y, Shen D, Gu Y, Zhong P, Xie J, Song Q. The diagnostic value of Ki-67, P53 and P63 in distinguishing partial Hydatidiform mole from hydropic abortion. Wien Klin Wochenschr. 2012;124(5–6):184–7.
Rübsam M, Mertz AF, Kubo A, Marg S, Jüngst C, Goranci-Buzhala G, et al. E-cadherin integrates mechanotransduction and EGFR signaling to control junctional tissue polarization and tight junction positioning. Nat Commun. 2017;8(1):1–16.
Dubruc E, Allias F, Morel AP, Golfier F, Puisieux A, Devouassoux-Shisheboran M. Gestational trophoblastic neoplasms (GTNs) do not display epithelial-to-mesenchymal transition (EMT) features. Virchows Arch. 2019;475(1):121–5.
Mendonsa AM, Na TY, Gumbiner BM. E-cadherin in contact inhibition and cancer. Oncogene. 2018;37(35):4769–80.
Shu H, Chen H, Yang B, Chang Z, Xiong M, Chen W. Aberrant expression of E-cadherin and integrin ?-1 in trophoblasts is associated with malignant gestational trophoblastic diseases. Int J Gynecol Cancer. 2013;23(4):749–54.
Chen X, Huang J, Peng Y, Han Y, Wang X, Tu C. The role of circRNA polyribonucleotide nucleoside transferase 1 on Gestational Diabetes Mellitus. Cell Mol Biol (Noisy-le-grand). 2022;68(6):148–54.
P?ksa M, Kamieniecki A, Gabrych A, Lew?tusk A, Preis K, ?wi?tkowska?freund M. Loss of E?Cadherin Staining Continuity in the Trophoblastic Basal Membrane Correlates with Increased Resistance in Uterine Arteries and Proteinuria in Patients with Pregnancy?Induced Hypertension. J Clin Med. 2022;11(3):668.
Shahbazi MN, Wang T, Tao X, Weatherbee BAT, Sun L, Zhan Y, et al. Developmental potential of aneuploid human embryos cultured beyond implantation. Nat commun. 2020;11(1):3987.
Burandt E, Lübbersmeyer F, Gorbokon N, Büscheck F, Luebke AM, Menz A, et al. E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. Biomark Res. 2021;9(1):1–17.
Saito T, Masuda N, Miyazaki T, Kanoh K, Suzuki H, Shimura T, et al. Expression of EphA2 and E-cadherin in colorectal cancer: Correlation with cancer metastasis. Oncol Rep. 2004;11(3):605–11.
dos Reis ST, Leite KRM, Neto AM, Júnior JP, Viana NI, Antunes AA, et al. Immune expression of E-cadherin and ?, ? and ?-Catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas. Int braz j urol. 2012;38(4):466–73.
Horne HN, Oh H, Sherman ME, Palakal M, Hewitt SM, Schmidt MK, et al. E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Sci Rep. 2018;8(1):1–11.
Kushwaha S, Joshi S, Arora K, Kushwaha N, Sharma S, Saini D. Correlation of E-cadherin Immunohistochemical Expression with Histopathological Grading of Oral Squamous Cell Carcinoma. Contemp Clin Dent. 2019;10(2):232.
Otali D, Fredenburgh J, Oelschlager DK, Grizzle WE. A standard tissue as a control for histochemical and immunohistochemical staining. Biotech Histochem. 2016;91(5):309–26.
Miller RT. Avoiding pitfalls in diagnostic immunohistochemistry-important technical aspects that every pathologist should know. Semin Diagn Pathol. 2019;36(5):312–35.
Halilovic A, Bulte J, Jacobs Y, Braam H, Van Cleef P, Schlooz-Vries M, et al. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu. J Clin Pathol. 2017;70(9):781–6.
DOI: 10.5457/ams.v55i1.688
